← All trials
NCT01210456
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2009
- Primary completion
- Oct 1, 2014
- Completion date
- Nov 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 458
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Tokushukai Medical GroupLead sponsor
- Sapporo Higashi Tokushukai HospitalOverall official - principal investigator
- Tokushukai Medical GroupReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.